NGS already has the capacity to ameliorate genetic screening in families who have histories of greater occurrence of various cancer-associated genes including TP53, APC, BRCA2, and BRCA1 (Meldrum et al., 2011[49]). This evidence concerns the gene BRCA2 and cancer.